Compare Kinross Gold Corporation (KGC) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kinross Gold Corporation vs Merck & Co., Inc. — how do they compare? Kinross Gold Corporation trades at $23.69 (market cap $27.62B), while Merck & Co., Inc. trades at $146.31 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 12.7× Kinross Gold Corporation's market cap, and Merck & Co., Inc. pays the higher dividend (2.39%). Which is the better fit depends on your goals — on Pluang, investors hold Kinross Gold Corporation for 53 Days and Merck & Co., Inc. for 98 Days on average.
| KGC | MRK | |
|---|---|---|
Market Cap | $27.62B | $351.28B |
Volume | 6,347,266 | 7,969,665 |
Sector | Basic Materials | Health |
52-Week High | $38.06 | $156.43 |
52-Week Low | $22.47 | $82.49 |
Typical Hold Time | 53 Days | 98 Days |
Enterprise Value | $25.70B | $398.04B |
Dividend Yield | 0.69% | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kinross Gold (KGC) trades at $23.82, up 2.76% today, but faces a bearish technical signal despite strong fundamentals. The company reported robust earnings, beating estimates for three consecutive quarters, with 2025 revenue of $7.05 billion and net income of $2.39 billion. However, recent news highlights production guidance cuts and legal investigations, creating mixed sentiment. Valuation ratios appear attractive with a P/E of 8.87 and EV/EBITDA of 4.59, while analyst consensus remains bullish with a $38.80 price target.
The outlook for KGC is cautiously optimistic, driven by strong cash flow and gold price resilience, but near-term risks include operational setbacks and legal overhangs. Investment opportunity lies in its undervaluation and shareholder returns, yet investors must weigh production volatility and cost pressures against fundamental strength.
Merck (MRK) trades at $144.96, up 1.52% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 72.97% gross margin and 28.07% net income margin for 2025, though its P/E ratio of 113.9 indicates high valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid competitive pressures.
The outlook is mixed: analyst consensus is bullish with a $158.78 price target, but technical indicators and a high P/E suggest near-term caution. Key risks include integration challenges from acquisitions and macroeconomic headwinds affecting pharmaceutical R&D investment. Revenue growth and pipeline execution remain critical for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kinross Gold Corporation
Kinross Gold is a Canada-based senior gold producer, producing roughly 2.4 million gold equivalent ounces in 2020. The company had 30 million ounces of proven and probable gold reserves and 59 million ounces of silver reserves at the end of 2020. It operates mines and focuses its greenfield and brownfield exploration in the Americas, West Africa, and Russia. The company has historically used acquisitions to fuel expansion into new regions and production growth.
Read more on KGC →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
